MCID: VSC004
MIFTS: 29

Vasculogenic Impotence

Categories: Cardiovascular diseases, Mental diseases

Aliases & Classifications for Vasculogenic Impotence

MalaCards integrated aliases for Vasculogenic Impotence:

Name: Vasculogenic Impotence 12 15 17
Impotence, Vasculogenic 44 71

Classifications:



External Ids:

Disease Ontology 12 DOID:4762
MeSH 44 D018783
UMLS 71 C0243000

Summaries for Vasculogenic Impotence

MalaCards based summary : Vasculogenic Impotence, also known as impotence, vasculogenic, is related to impotence and priapism. An important gene associated with Vasculogenic Impotence is PDE5A (Phosphodiesterase 5A), and among its related pathways/superpathways are Metabolism of nucleotides and Renin secretion. The drugs Everolimus and Immunosuppressive Agents have been mentioned in the context of this disorder. Affiliated tissues include smooth muscle, skin and endothelial.

Related Diseases for Vasculogenic Impotence

Diseases related to Vasculogenic Impotence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 67)
# Related Disease Score Top Affiliating Genes
1 impotence 30.7 PDE5A PDE4A ALDH7A1 ACE
2 priapism 30.5 PDE5A ADA
3 peyronie's disease 10.2
4 venous insufficiency 10.2
5 vascular disease 10.2
6 bladder neck obstruction 10.1 PDE5A ACE
7 pulmonary valve insufficiency 10.1 PDE5A ACE
8 raynaud disease 10.1 PDE5A ACE
9 chronic pulmonary heart disease 10.1 PDE5A ACE
10 tricuspid valve disease 10.1 PDE5A ACE
11 tricuspid valve insufficiency 10.1 PDE5A ACE
12 retinitis pigmentosa 72 10.1 PDE5A ALDH7A1
13 psychosexual disorder 10.1 PDE5A ALDH7A1
14 constrictive pericarditis 10.1 ADA ACE
15 pericarditis 10.1 ADA ACE
16 cardiac tamponade 10.1 ADA ACE
17 nonarteritic anterior ischemic optic neuropathy 10.1 PDE5A ACE
18 limited scleroderma 10.1 PDE5A ACE
19 pericardium disease 10.0 ADA ACE
20 hypoaldosteronism 10.0 NPPA ACE
21 anterolateral myocardial infarction 10.0 NPPA ACE
22 idiopathic edema 10.0 NPPA ACE
23 buerger disease 10.0
24 arteriosclerosis 10.0
25 intermittent claudication 10.0
26 renal artery disease 10.0 NPPA ACE
27 inappropriate adh syndrome 10.0 NPPA ACE
28 central sleep apnea 10.0 NPPA ACE
29 aortic valve insufficiency 10.0 NPPA ACE
30 mitral valve stenosis 10.0 NPPA ACE
31 acute kidney tubular necrosis 10.0 NPPA ACE
32 mitral valve insufficiency 10.0 NPPA ACE
33 hepatorenal syndrome 10.0 NPPA ACE
34 tuberculous meningitis 10.0 NPPA ADA
35 malignant hypertension 10.0 NPPA ACE
36 renovascular hypertension 10.0 NPPA ACE
37 systolic heart failure 10.0 NPPA ACE
38 hypertensive heart disease 10.0 NPPA ACE
39 mitral valve disease 9.9 NPPA ACE
40 pulmonary edema 9.9 NPPA ACE
41 parkinson disease 1, autosomal dominant 9.9 PDE5A PDE4A
42 heart valve disease 9.9 NPPA ACE
43 hypoplastic left heart syndrome 9.9 NPPA ACE
44 intrinsic cardiomyopathy 9.9 NPPA ACE
45 aortic valve disease 2 9.9 NPPA ACE
46 atrial heart septal defect 9.8 NPPA ACE
47 acrodysostosis 9.8 PDE4A ALDH7A1
48 gaucher's disease 9.8 ADA ACE
49 trypanosomiasis 9.8 NPPA ADA
50 pure autonomic failure 9.8 PDE5A NPPA ACE

Graphical network of the top 20 diseases related to Vasculogenic Impotence:



Diseases related to Vasculogenic Impotence

Symptoms & Phenotypes for Vasculogenic Impotence

Drugs & Therapeutics for Vasculogenic Impotence

Drugs for Vasculogenic Impotence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):


# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Everolimus Approved Phase 2, Phase 3 159351-69-6 6442177 70789204
2 Immunosuppressive Agents Phase 2, Phase 3
3 Immunologic Factors Phase 2, Phase 3
4
Coal tar Approved Phase 1, Phase 2 8007-45-2
5 Anesthetics Phase 1, Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Safety and Feasibility of Bioabsorbable Everolimus-Eluting Stents for Patients With Internal Pudendal Artery-Related Arteriogenic Erectile Dysfunction (PERFECT-ABSORB) Unknown status NCT02492386 Phase 2, Phase 3
2 Effectiveness and Safety of Intracavernosal Administration of Autologous Adipose-Derived Regenerative Cells for Treatment of Erectile Dysfunction Completed NCT02472431 Phase 1, Phase 2

Search NIH Clinical Center for Vasculogenic Impotence

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Alprostadil
Pentoxifylline
sildenafil
Sildenafil citrate

Cochrane evidence based reviews: impotence, vasculogenic

Genetic Tests for Vasculogenic Impotence

Anatomical Context for Vasculogenic Impotence

MalaCards organs/tissues related to Vasculogenic Impotence:

40
Smooth Muscle, Skin, Endothelial

Publications for Vasculogenic Impotence

Articles related to Vasculogenic Impotence:

(show top 50) (show all 222)
# Title Authors PMID Year
1
Hybrid Endovascular Aortic Aneurysm Repair: Preservation of Pelvic Perfusion with External to Internal Iliac Artery Bypass. 61
28286187 2017
2
[Aorto-femoral reconstructions in patients with vasculogenic impotence and quality of life]. 61
29898292 2017
3
Endovascular treatment of vasculogenic erectile dysfunction. 61
25532580 2015
4
Sympathetic skin response in patients with vascular erectile dysfunction. 61
24872950 2014
5
Nocturnal penile erections: the role of RigiScan in the diagnosis of vascular erectile dysfunction. 61
23206346 2012
6
The role of Doppler ultrasound in the diagnosis of vasculogenic impotence. 61
21341552 2010
7
Office management of peripheral arterial disease. 61
20800143 2010
8
Predictive value of cavernosal peak systolic velocity in the flaccid penis. 61
19808161 2009
9
Feasibility of dynamic 3-D color Doppler ultrasound for imaging penile vascular change in renal transplant patients with erectile dysfunction responding to sildenafil. 61
18295391 2008
10
Purification of a dimethyladenosine compound from silkworm pupae as a vasorelaxation substance. 61
18337035 2008
11
Vasculogenic impotence as a symptom in late-onset Buerger's disease. 61
17486572 2007
12
Penile oxygen saturation in the flaccid and erect penis in men with and without erectile dysfunction. 61
17021333 2007
13
Management of peripheral arterial disease of the lower extremities. 61
18025617 2007
14
Peripheral arterial disease in the elderly. 61
18225466 2007
15
Corpus cavernosum from men with vasculogenic impotence is partially resistant to adenosine relaxation due to endothelial A(2B) receptor dysfunction. 61
16837560 2006
16
The penile vasculature in systemic sclerosis: A duplex ultrasound study. 61
16681482 2006
17
Automated bedside measurement of penile blood flow using pulse-volume plethysmography. 61
16493536 2006
18
Management of peripheral arterial disease. 61
15705252 2005
19
Erectile dysfunction: anatomical parameters, etiology, diagnosis, and therapy. 61
15764414 2005
20
Management of peripheral arterial disease of the lower extremities in elderly patients. 61
14999033 2004
21
Sildenafil preserves intracorporeal smooth muscle after radical retropubic prostatectomy. 61
14713808 2004
22
Autonomic nerve preserving total mesorectal excision. 61
12507206 2002
23
Penile colour duplex ultrasonography as a screening tool for venogenic erectile dysfunction. 61
11957552 2002
24
Decreased trabecular smooth muscle and caveolin-1 expression in the penile tissue of aged rats. 61
11458126 2001
25
Therapeutic effects of high-dose isoxsuprine in the management of mixed-type impotence. 61
11445487 2001
26
Vasculogenic impotence. Arterial and venous surgery. 61
11402583 2001
27
Hemodynamic insult by vascular risk factors and pharmacologic erection in men with erectile dysfunction: Doppler sonography study. 61
11204263 2000
28
[Doppler color ultrasonography in patients with erectile dysfunction]. 61
11221074 2000
29
Vasculogenic impotence and cavernosal oxygen tension. 61
11052643 2000
30
Vasculogenic impotence and cavernosal oxygen tension. 61
10982308 2000
31
Retrospective review of flow patterns following retropubic prostatectomy. 61
10637457 1999
32
Assessment of the functional role of accessory pudendal arteries in erection by transrectal color Doppler ultrasound. 61
10569553 1999
33
Evaluation and therapeutic approaches of voiding and erectile dysfunction in neurological Behçet's syndrome. 61
10379759 1999
34
Recent advancement in diagnosis of vasculogenic impotence. 61
11225903 1999
35
[Revascularization of the corpora cavernosa in vasculogenic impotence]. 61
10429426 1999
36
Penile arteriography. 61
10458660 1999
37
Predictive value of patient history and correlation of nocturnal penile tumescence, colour duplex Doppler ultrasonography and dynamic cavernosometry and cavernosography in the evaluation of erectile dysfunction. 61
10098954 1999
38
Is obesity an underlying factor in erectile dysfunction? 61
10364658 1999
39
Venous incompetence in erectile dysfunction: evaluation with color-coded duplex sonography and cavernosometry/-graphy. 61
9933376 1999
40
Technetium-99m-labelled RBC erection penogram to differentiate psychogenic from vasculogenic impotence. 61
9792979 1998
41
[Methodology of penile isotope imaging. Evaluation]. 61
9611353 1998
42
Cavernous arterial and arteriolar circulation in patients with erectile dysfunction: a power Doppler study. 61
9649256 1998
43
Laparoscopically assisted penile revascularization for vasculogenic impotence: 2 additional cases. 61
9334601 1997
44
Intracavernosal forskolin: role in management of vasculogenic impotence resistant to standard 3-agent pharmacotherapy. 61
9334594 1997
45
Microrevascularisation of the penis in vascular impotence. 61
9315489 1997
46
Penile revascularisation for vascular impotence. 61
9339093 1997
47
Laparoscopic mobilization of the inferior epigastric artery for penile revascularization in vasculogenic impotence. 61
9250921 1997
48
Relationship between cavernosal ischemia and corporal veno-occlusive dysfunction in an animal model. 61
9072535 1997
49
[Diagnostic methods and therapeutic options in vasculogenic impotence]. 61
9102618 1997
50
Glans hyperemia after penile revascularization: a late complication following alpha-1-receptor blockade for benign prostatic hyperplasia. 61
9058525 1997

Variations for Vasculogenic Impotence

Expression for Vasculogenic Impotence

Search GEO for disease gene expression data for Vasculogenic Impotence.

GO Terms for Vasculogenic Impotence

Biological processes related to Vasculogenic Impotence according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of blood pressure GO:0008217 8.96 ACE NPPA
2 positive regulation of heart rate GO:0010460 8.62 NPPA ADA

Molecular functions related to Vasculogenic Impotence according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hydrolase activity GO:0016787 9.46 PDE5A PDE4A ADA ACE
2 phosphoric diester hydrolase activity GO:0008081 8.96 PDE5A PDE4A
3 3',5'-cyclic-nucleotide phosphodiesterase activity GO:0004114 8.62 PDE5A PDE4A

Sources for Vasculogenic Impotence

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....